## 1 Markers of systemic iron status show sex-specific differences in peripheral artery

- 2 disease: a cross-sectional analysis of HEIST-DiC and NHANES participants
- 4
- 5 Anand Ruban Agarvas<sup>1</sup>, Stefan Kopf<sup>2,3</sup>, Paul Thalmann<sup>4</sup>, José Manuel Fernández-
- 6 Real<sup>5</sup>, Peter Nawroth<sup>2,3</sup>, \*Martina U. Muckenthaler<sup>1,6,7,8</sup>
- 7
- 8 Affiliations

<sup>9</sup> <sup>1</sup>Center For Translational Biomedical Iron Research, Department of Pediatric Hematology,

- 10 Oncology Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, 11 Germany.
- <sup>2</sup>Clinic for Endocrinology, Diabetology, Metabolic Diseases and Clinical Chemistry (Internal
   Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
- <sup>14</sup> <sup>3</sup>German Center of Diabetes Research (DZD), Neuherberg, Germany.
- <sup>4</sup>Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
- <sup>5</sup>Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de
- Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona
   17007, Spain.
- <sup>6</sup>Molecular Medicine Partnership Unit, Heidelberg, Germany.
- <sup>7</sup>Translational Lung Research Center Heidelberg (TLRC), German Center for Lung
   Research (DZL), University of Heidelberg, Heidelberg, Germany.
- <sup>8</sup>German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim,
   Germany.
- 24
- 25 \*Corresponding author
- 26
- 27

## 28 Address for correspondence

- 29 Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg,
- 30 Heidelberg, Germany.
- 31 Tel.: +496221566923; Fax: +496221564580. E-mail: martina.muckenthaler@med.uni-
- 32 heidelberg.de (M.U. Muckenthaler).

#### 33 Abstract

34

## 35 Background

Iron has been proposed as a risk factor for atherosclerosis but the data are controversial. We previously showed that non-transferrin-bound iron (a fraction of iron appearing in iron overload) contributes to atherosclerosis. Here, we investigated whether iron within physiological limits influenced atherosclerosis by studying its association with vascular dysfunction and peripheral arterial disease (PAD). Further, we evaluated if this relationship was influenced by comorbidities.

42

## 43 Methods

We studied the association between iron biomarkers in blood and markers for vascular adhesion and PAD in 368 individuals registered in the Heidelberg Study on Diabetes and Complications (HEIST-DiC). Our observations were validated by analyzing the association between iron biomarkers and PAD in the National Health and Nutrition Examination Survey (NHANES 1999-2004) data.

49

## 50 Results

In both HEIST-DiC and NHANES cohorts, plasma ferritin levels are positively associated with PAD in females and not in males. We further identified negative associations between TIBC and plasma iron levels with PAD among females. These relationships were independent of the presence of other comorbidities including hypertension, insulin resistance, prediabetes, and diabetes.

## 56 Conclusion

We demonstrate a sex-specific alteration of markers of systemic iron availability in individuals with clinically apparent PAD implying that mechanisms of disease development may differ between males and females. Elevated ferritin levels and hypoferremia in females are indicative of an underlying inflammation that may affect the pathogenesis of PAD. The observed lack of a positive association of PAD with serum iron levels suggest that "physiological" iron concentrations are safe for vascular health.

63

## 64 Keywords

Iron, Vascular Diseases, Arterial Occlusive Diseases, Atherosclerosis, Peripheral Arterial
 Disease

#### 67 Introduction

Peripheral arterial disease (PAD) is a common atherosclerotic vascular disorder of the 68 arteries of the lower limbs and affects millions of individuals worldwide<sup>1,2</sup>. Unrecognized and 69 70 untreated PAD reduces blood flow to the lower extremities resulting in leg pain, impaired 71 mobility, and amputation. Moreover, it is associated with an increased risk of cardiovascular 72 morbidity and mortality<sup>3</sup>. Compared to cardiovascular and cerebrovascular disease, PAD is 73 less well studied, and our understanding of the disease process is still poor. Among the 74 known risk factors of PAD include old age, smoking, and comorbidities such as diabetes and hypertension<sup>1</sup>. A recent genome-wide association study<sup>4</sup> identified genetic loci that are 75 unique to PAD, in addition to those shared between the different atherosclerotic disorders 76 77 (coronary, cerebral, and peripheral) suggesting that additional mechanisms may contribute 78 to the pathophysiology of PAD.

79

80 Iron is an essential micronutrient and its homeostasis is controlled by regulatory systems 81 that maintain its absorption, transport, and storage<sup>5</sup>. If iron accumulates in excess, it 82 contributes to the generation of reactive oxygen species. Iron is, therefore, discussed as a 83 risk factor for the development of atherosclerosis and cardiovascular disease<sup>6</sup>. We 84 previously analysed mouse models and humans with iron overload disorder, 85 hemochromatosis, and found that excess iron played a multifaceted role in atherosclerosis 86 depending on the compartment where it is localized<sup>7</sup>. Under physiological conditions, iron is 87 bound to transferrin in the plasma, and is transported to those cells that require iron. Iron 88 occupies only one-third of transferrin's binding sites, therefore, free iron can be sequestered 89 in the circulation. However, in pathological states associated with iron overload, most binding 90 sites on transferrin are saturated resulting in the appearance of 'non-transferrin-bound iron 91 (NTBI)'. We found that NTBI in circulation contributes to atherosclerosis by oxidising lowdensity lipoproteins (LDL) and inducing vascular dysfunction<sup>7</sup>. In addition, iron deposition in 92 93 the vasculature of hemochromatotic mice was associated with enhanced atherosclerosis<sup>7</sup>. 94 An interesting open question is whether iron levels within physiological limits influence 95 atherogenesis. The available data is controversial.

96

97 The relationship between iron and atherosclerosis has been commonly studied by analyzing 98 the association of one or more iron biomarkers [e.g. plasma iron, ferritin, transferrin, 99 transferrin saturation (TSAT)] with atherosclerosis markers (e.g. coronary artery calcium or 100 carotid intima-media thickness)<sup>8–14</sup>. On the other hand, studies have also been performed 101 that consider blood donation as an iron-depletion strategy and evaluated atherosclerosis risk 102 in blood donors<sup>15–19</sup>. More recently, Gill *et al.* used a Mendelian randomization approach to

evaluate the risk of venous thromboembolism and carotid atherosclerosis with the
 genetically determined iron status<sup>14</sup>.

105

106 The relationship between iron and PAD is less well-studied. Menke et al. showed that ferritin 107 and TSAT are positively associated with PAD in the National Health and Nutrition 108 Examination Survey 1999-2002 (NHANES), especially among participants with elevated 109 cholesterol<sup>20</sup>. Among individuals on hemodialysis, one study found that PAD was associated with anemia and low iron levels<sup>21</sup> while the other found a positive association with ferritin 110 levels<sup>22</sup>. Results of a randomized controlled trial suggested that among participants with 111 established PAD, the iron reduction did not improve the clinical outcomes or mortality<sup>23</sup>. 112 113 Several open questions remain: Are there differences in how iron parameters influence 114 atherosclerosis at different sites? Do iron biomarkers correlate with the severity of PAD? If 115 so, how? How are these relationships influenced by sex or the presence of prediabetes or 116 diabetes?

117

Here we analyzed iron biomarkers within physiological limits for association with markers for vascular function and PAD in a cohort of individuals with diabetes and prediabetes enrolled in the Heidelberg Study on Diabetes and Complications (HEIST-DiC). We validated our observations by analyzing the NHANES 1999-2004 data.

122

#### 123 Methods

#### 124 **Participants**

#### 125 HEIST-DiC study

126 We retrospectively analysed the data from 368 individuals enrolled in the HEIST-DiC study 127 (Clinical trials.gov NCT03022721). The selection criteria for participants have been described previously<sup>24</sup>; in addition, we excluded those with values of serum iron biomarkers 128 suggestive of likely hemochromatosis<sup>25</sup>. For all participants, a detailed medical history was 129 130 obtained. The ankle-brachial index (ABI) was measured using noninvasive blood pressure 131 measurements of arms and ankles (ABI System 1000; Boso d.o.o.). Blood samples were 132 obtained in the fasting state and all baseline parameters were analyzed under standardized 133 conditions in the central laboratory of the University Hospital of Heidelberg. Serum samples 134 were stored at -80C until further analysis. We used iron, ferritin, and TSAT were used as 135 biomarkers of systemic iron status and serum intercellular adhesion molecule-1 (ICAM1) and 136 vascular-cell adhesion molecule-1 (VCAM1) were used as markers of vascular dysfunction. 137 We measured ICAM1 (#171B6009M) and VCAM1 (#171B6022M) using multiplex magnetic 138 bead-array-based technology on a BioPlex200 system (Bio-Rad) according to the 139 manufacturer's instructions. All participants provided written informed consent and the ethics

committees of the University of Heidelberg approved this study (Decision No. 204/2004,

141 400/2010, and S-383/2016) according to the Declaration of Helsinki.

#### 142 NHANES

143 NHANES is designed to assess the health and nutritional status of adults and children in the 144 United States. The survey includes both an interview component, in which participants are 145 asked questions about their health and lifestyle, and a physical examination component, in 146 which various measurements and samples are collected. We obtained data from 15969 147 participants over 40 years in 3 consecutive cycles of NHANES (1999-2004) for whom ABI was measured. We applied the following exclusion criteria: not even one ABI measurement 148 149 available, likely hemochromatosis<sup>25</sup>, anemia (hemoglobin <10g/L), on current hormonal 150 medications or iron supplements, cancer, donated blood in the last 1 month, with features of 151 kidney disease (on dialysis or severe albuminuria), pregnant or breastfeeding in the last 152 vear, high risk of liver fibrosis, concurrent inflammation [C-Reactive Protein (CRP) >3ug/L] 153 and with a feature of familial hyperlipidemia [LDL-Cholesterol (LDLc) >4.9mM]. This resulted 154 in a final sample number of 9336 participants. We obtained data from the following iron 155 biomarkers rom NHANES: iron, ferritin, total iron binding capacity (TIBC), and TSAT.

156

157 Among the demographic variables, age (in years) and body mass index (BMI) were obtained 158 and used as is from NHANES. Smoking and alcohol were categorized according to a 159 previous study<sup>26</sup>. We categorized diabetes based on self-reported history, current use of 160 insulin or oral hypoglycemic agents, fasting plasma glucose (FPG) ≥7.0 mM, or glycated 161 hemoglobin (HbA1c) ≥6.5%. Prediabetes was defined among those with an absent self-162 reported history of diabetes and one of the following: FPG 5.6-6.9 mM or HbA1c 5.7-6.4%. 163 We categorized hypertension based on self-reported history or current use of anti-164 hypertensive agents or systolic blood pressure >130 mmHg or diastolic blood pressure >80 165 mmHq. The presence of nonalcoholic fatty liver disease (NAFLD) was categorized by calculating FIB-4 score<sup>27</sup>. Assays for the analytes in NHANES were performed under strict 166 167 laboratory protocols (for more details on data fields and procedure manuals, see 168 Supplementary Table 2). As an index of insulin resistance, we calculated HOMA2-IR using C-peptide values instead of insulin<sup>28</sup>. 169

170

### 171 Categorization as PAD

172 In both cohorts, ABI values were measured on both the right and left limbs. We categorized

- 173 PAD when the ABI value on one of the sides was <0.9 or >1.4 as per recommendations<sup>29</sup>.
- 174
- 175 Statistical analysis

For the analysis of participants in both cohorts, the following aspects were similar: we modelled the probability of PAD's presence with one of the iron biomarkers (iron, ferritin, or TSAT) by logistic regression using a nested approach. Since iron metabolism shows sexspecific differences, we conducted a sex-stratified analysis. In general, we included variables that are known to affect iron homeostasis or the risk of PAD as covariates. Further, all continuous variables were mean-centered for the analysis, and variables were included in the models only when their missing data was <10%.

183

184 Some study-specific aspects of the analysis are described below. For the HEIST-DiC study, 185 we built 3 different regression models that analysed the association between iron biomarkers 186 and PAD or markers of vascular dysfunction (ICAM1, VCAM1). Model 1 was univariate. 187 Model 2 was built on model 1 by adjusting for demographic variables: sex (males as 188 reference), presence of diabetes, and hypertension (absence of disease as reference). 189 Model 3 was built on Model 2 by including additional covariates [high sensitivity CRP 190 (hsCRP), LDLc, HbA1c, and urine albumin creatinine ratio (ACR); all continuous]. As 191 subgroup analysis in the HEIST-DiC cohort, we conducted univariate regression for iron 192 parameters only in individuals with diabetes; we did not conduct a subgroup analysis for 193 prediabetes since the number of patients with PAD in this group was small (2/23).

194

195 For the NHANES data, only the association between iron biomarkers and PAD was 196 analyzed. Model 1 represents the univariate analysis, while models 2-4 are multivariate. 197 Model 2 was built on model 1 by adjusting for demographic variables (age, BMI, smoking 198 (non-smokers as reference), and ethnicity (non-Hispanic whites as the reference). Model 3 199 was built on model 2 by incorporating the following covariates (as categorical: the presence 200 of diabetes, and hypertension (absence of disease as reference), FIB4 score [<1.2 as 201 reference]; as continuous: CRP, ACR. Model 4 was built on model 3 by including HOMA2-202 IR, LDLc, use of antihyperlipidemic and antiplatelet agents (the former two variables as 203 continuous and the latter two as categorical). For the NHANES dataset, we also conducted a 204 sensitivity analysis by conducting the analyses on the whole cohort without the exclusion of 205 data. In addition, sample weights were included all the analyses.

206

A p-value<0.05 was considered statistically significant. All statistical analyses and visualizations were performed using R Statistical Software (v4.2.2<sup>30</sup>). Reporting of the study is as per The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines<sup>31</sup>. We have also developed a data exploration tool for readers to explore the datasets and interactively create their visualizations from the paper (https://anandr.shinyapps.io/NHANES HEISTDiC/) using Quarto<sup>32</sup> and Shiny<sup>33</sup>.

#### 213

#### 214 Results

## 215 HEIST-DiC study

216 The HEIST-DiC is a prospective, observational study designed to analyze the development of 217 complications in individuals with diabetes and prediabetes. We investigated the relationship 218 between systemic iron biomarkers and PAD in the baseline data and the participant 219 characteristics are shown in Table 1. The overall prevalence of PAD was 6.6% with a higher 220 proportion among males (17/192) than females (6/165). Among both sexes, the participants 221 with PAD were older and a majority of them also had associated diabetes and hypertension; 222 the proportion of individuals with prediabetes and PAD was small (Table 1). Vascular 223 adhesion markers such as ICAM1 and VCAM1 were significantly higher only among the 224 males with PAD (Table 1). Among the iron biomarkers, ferritin was elevated among females 225 with PAD while iron, transferrin, and TSAT were not significantly different. Of note, significant 226 differences between iron parameters and PAD were not noted in males.

227

228 In the regression analyses, ferritin was associated with an increased probability of PAD in 229 females but not males (Figure 1). This positive association was significant in models 1 and 2 230 (Model 1: OR 3.23, 95% CI 1.23-8.7, P=0.013, Model 2: OR 2.87, 95% CI 0.96-9.18, 231 P=0.06) however, an increased risk was also evident in the Model 3 (OR 1.86, 95% CI 0.38-232 8.1, P=0.4). The positive association of ferritin with PAD persisted in models adjusted for the 233 comorbidities diabetes and hypertension (Model 2 and Model 3); further, ferritin also showed 234 a tendency for a positive association in the diabetes subgroup (OR 2.44, 95% CI 0.8-7.14, 235 P=0.09). On the other hand, iron and TSAT did not show a significant association with PAD 236 in either sex (Figure 1). In contrast to our previous observations in individuals with 237 hemochromatosis<sup>7</sup>, markers of vascular dysfunction such as ICAM1 and VCAM1 were not 238 significantly associated with iron parameters within physiological ranges (iron, ferritin, or 239 TSAT) in both sexes (Figures 2-3).

240

#### 241 **NHANES**

This part of the study builds upon a previous analysis of the NHANES 1999-2002 cycles by 242 Menke et al.<sup>20</sup> by including data from the NHANES 2003-2004 cycle. The baseline 243 244 characteristics of the NHANES 1999-2004 participants included in the study are shown in 245 Table 2. Overall, the prevalence of PAD in the population was 6.25% with a significantly 246 higher prevalence among females (males: 4.96%, females: 7.9%; p=0.001). Among 247 individuals with PAD, we observed differences in ethnicity, sex, presence of diabetes, 248 smoking, alcohol status, physical activity, and use of antihyperlipidemic and antiplatelet 249 medications (Table 2). The prevalence of PAD increased with older age (median: 69 for

males, P<0.001; 71 for females, P<0.001) with a higher percentage from the non-Hispanic</li>
white ethnicity (84% for males, P=0.003; 78% for females, P=0.005). BMI was significantly
higher among females with PAD while it was not different for males (median: 28 for males, P
=0.8; 29 for females, P=0.014). The proportion of alcohol drinkers was comparable for both
sexes and was not statistically different (5.2% for males, P=0.6; 6% for females, P>0.9).

255

256 Among both sexes, the proportion of PAD participants with prediabetes (2.4% for males; 257 2.7% for females) or diabetes (2.3% for males; 3.0% for females) were comparable. The overall prevalence of hypertension was higher among those with PAD (9.9% of males, 258 259 p=0.003; and 11.8% of females, p=0.6). Smoking status was different among the sexes in 260 the PAD group: among males, the proportion of former and current smokers was significantly 261 higher (Non-smokers 1.7%, Former smokers 4.2%, Current smokers 2.3%; P<0.001) while 262 the distribution was not different among females (Non-smokers 5.4%, Former smokers 3.1%, 263 Current smokers 1.8%; P=0.2). As expected, lower physical activity was also associated with 264 PAD in both sexes (50% of males and 57% of females). Among both sexes, the PAD 265 subgroup also had a higher FIB4 score indicating a greater degree of liver fibrosis (Males: 266 1.35, P<0.001; Females: 1.14 P<0.001).

267

Among the iron biomarkers, serum iron (Median 80, IQR 64-108  $\mu$ g/dL; P<0.001) and transferrin saturation (Median 24, IQR 17-30; P=0.021) were lower in males with PAD while females with PAD showed higher ferritin (Median 87, IQR 56-252 ng/mL; P<0.001) and lower TIBC (Median 60, IQR 54-68; P<0.001). Marginal differences were also observed in some laboratory parameters within both sexes with PAD (e.g. albumin, AST, urea, creatinine, C-reactive protein, and albumin-creatinine ratio; Table 2).

274

275 Consistent with our observations in the HEIST-DiC cohort, serum ferritin levels showed a 276 positive association with PAD only in females (Figure 4). This positive association was 277 strongest in Model 4, the most complex regression model we built (OR 3.6, 95% CI 1.25-278 10.6, P=0.018). Interestingly, TIBC analysis showed a significant negative association with 279 PAD only among females (OR 0.71, 95% CI 0.58-0.88, P=0.002; Model 2: OR 0.63, 95% CI 280 0.5-0.79, P<0.001; Model 3: OR 0.56, 95% CI 0.41-0.75, P<0.001; Model 4: OR 0.29, 95% 281 CI 0.12-0.7, P=0.006; Figure 4). By contrast, none of the associations for ferritin and TIBC 282 were significant for males. On the other hand, serum iron levels (Figure 4), were negatively 283 associated with PAD in both females (Model 1: OR 0.75, 95% CI 0.61-0.92, P=0.005; Model 284 2: OR 0.77, 95% CI 0.61-0.98, P=0.034; Figure 4) and males (Model 1: OR 0.79, 95% CI 285 0.62-1, P=0.046). For TSAT, a positive association for females was observed in Model 4 286 (OR 2.87, 95% CI 1.15-6.92, P=0.023) while a negative association was noted for males

287 (Model 1: OR 0.75, 95% CI 0.61-0.93, P=0.008; Model 2: OR 0.8, 95% CI 0.64-0.99,
288 P=0.041; Figure 4).

289

290 We next analysed associations of other covariates with PAD from Model 4 (Supplementary 291 Table 1). Of note, BMI had no association with PAD, while smoking showed a positive 292 association among both sexes that was more pronounced in males; interestingly, male 293 former smokers showed a negative association with PAD although, a positive association 294 still remained among females (Supplementary Table 1). Furthermore, the presence of 295 prediabetes was positively associated with PAD among males and negatively among 296 females; on the other hand, the presence of diabetes was negatively associated with PAD in 297 both sexes. HOMA2-IR showed positive associations among both males and females while 298 CRP showed a positive association mainly among females (Supplementary Table 1).

299

#### 300 Sensitivity analysis

To test the robustness of the relationships, we conducted a sensitivity analysis on the whole NHANES 1999-2004 cohort without applying any exclusion criteria. Here, we found that ferritin (in Model 1) and TIBC's observations in females (Models 1-3) were robust enough to retain their significant relationships (Supplementary Figure 1).

305

## 306 Discussion

While the majority of studies undertaken so far have focused on the relationship between iron and cardiovascular disease, only a few studies have investigated the role of iron in the development of atherosclerosis: furthermore, the topic of how iron biomarkers correlate with PAD, specifically, is rarely addressed. We, therefore, analyzed the data from two patient cohorts: HEIST-DiC and NHANES. Since iron parameters show important sex-specific differences, we conducted stratified analyses for males and females and additionally analysed if prediabetes or diabetes affected the observed relationships.

314

315 There were no significant associations between iron parameters within the physiological 316 range and markers of vascular dysfunction (ICAM1 or VCAM1), despite their elevated levels 317 in males with PAD. However, we observed sex-specific associations of iron biomarkers with 318 PAD, a relationship that was independent of the presence of other comorbidities including 319 hypertension, insulin resistance, prediabetes, and diabetes (Supplementary Table 1). In 320 both, the HEIST-DiC and NHANES patient cohorts, plasma ferritin levels are positively 321 associated with PAD in females and not in males. The positive association for higher serum 322 ferritin among females with PAD reported here strengthens the previous observations on the NHANES 1999-2001 cohort<sup>20</sup> and agrees with a previous study on carotid atherosclerosis<sup>34</sup>. 323

324 These findings are also, at least, partially consistent with studies that report ferritin's positive 325 association with carotid/coronary atherosclerosis. These studies do not observe major sex-326 specific differences<sup>8,12,13</sup>. On the contrary, the lack of a predictive role for ferritin in males is 327 in contrast to a previous study which reports a "U-shaped" relationship with cardiovascular disease among males<sup>35</sup>. The sex-specific associations of ferritin identified in the patient 328 329 cohorts described here also contrast findings in two other large cohort studies: i) a Danish 330 cohort that observed an increased risk of all-cause mortality for ferritin among both males 331 and females<sup>36</sup> and ii) a British cohort that observed an increased risk of cardiovascular 332 mortality among males with high ferritin and increased all-cause mortality among females with low ferritin<sup>37</sup>. 333

334

335 Interestingly, in the NHANES cohort, we further identified negative associations between 336 TIBC with PAD in females but not in males. This relationship between TIBC and PAD was 337 strong and robust, as evident from the sensitivity analysis (Figure 4; Supplementary Figure 338 1). Our findings thus support two previous studies that have analyzed the relationship 339 between TIBC and atherosclerosis <sup>12,38</sup>. Further, among both sexes, plasma iron showed a 340 negative association with PAD. The following studies on plasma iron and PAD do show 341 similar negative associations but have not investigated sex-specific differences. For 342 example, serum iron levels were reduced in hemodialysis patients with PAD ( $9.9 \Box \pm \Box 3.0 \mu M$ ) compared to those without PAD (11.5 $\pm$ 2.3  $\mu$ M; p=0.004)<sup>21</sup>. The study by Vega De Céniga 343 344 et al. also observed a higher prevalence of iron deficiency (31.9% with iron <58 mcg/dL) and 345 anemia (49.5%) among PAD participants<sup>39</sup>.

346

347 In our analyses, the association for TSAT with PAD showed contrasting observations in 348 males and females. While the HEIST-DiC cohort had insignificant associations for TSAT 349 (Figure 3), the NHANES cohort showed a positive association among females in Model 4 350 while the association was negative among males (Figure 4). Otaki et al. reported reduced 351 TSAT levels in PAD in a Japanese patient cohort and also found a correlation between TSAT with the severity of PAD<sup>40</sup>. Similar negative associations with TSAT have also been 352 made in the context of cardiovascular disease in both sexes<sup>11,12,14,41</sup>. For the interpretation of 353 354 TSAT, it is also important to consider that it is a calculated measure<sup>42</sup>. While the HEIST-DiC 355 study applied a formula including measured transferrin levels, the NHANES cohort used a 356 formula applying TIBC. Therefore, we are cautious in interpreting the associations of TSAT 357 in our study.

359 Our data extend on our previous findings, where we observed a striking correlation of NTBI and vascular dysfunction and atherosclerosis.<sup>7,43</sup> From this current study we conclude that 360 serum iron levels within physiological limits are safe for vascular health. These findings 361 362 agree with our previous proposed model<sup>7</sup> that only the labile iron fractions in the circulation 363 (eg., NTBI) in iron-loaded states plays a pathological role. Nevertheless, the associations 364 between iron biomarkers with PAD in females have several important implications. If ferritin 365 were interpreted as an indicator of body iron stores, our study suggests that there is an 366 increased risk of PAD at the upper end of, what is clinically accepted as a "physiological" 367 iron status. This finding would directly contrast our observation on the negative relationship between PAD and iron/TIBC which implies an increased PAD risk in iron-deficient states. 368 369 This could be interpreted as an "U-shaped" relationship between iron status and 370 cardiovascular disease as noted in two previous studies investigating the NHANES cohort<sup>41,44,45</sup>. However, ferritin is also an acute phase reactant with increased expression in 371 conditions of inflammation<sup>46</sup>. In inflammatory conditions, hypoferremia (low iron levels in the 372 373 plasma) arises from a reduced iron export via ferroportin from macrophages and duodenal 374 enterocytes by hepcidin-controlled<sup>47</sup> and transcriptional mechanisms<sup>48,49</sup>. Consequently, iron-exporting cells such as macrophages become iron loaded contributing to elevated 375 ferritin levels<sup>50</sup>. Overall, our findings may also suggest an iron redistribution in response to 376 377 an underlying inflammation that may render individuals more susceptible to PAD. Although 378 we excluded samples with CRP<3 mg/dL and used CRP as a covariate, the presence of 379 microinflammation in tissues cannot be completely excluded from the available data.

380

381 We further need to interpret our findings in the context of The Iron and Atherosclerosis Study 382 (FeAST; www.clinicaltrials.gov, Identifier NCT00032357), a major trial that investigated the 383 benefits of iron reduction on the clinical outcomes in a cohort of individuals with PAD<sup>23</sup>. 384 While the initial analysis of the FeAST trial results did not report a favorable outcome 385 following phlebotomy<sup>23</sup>, the reanalysis of the results adjusting for the effects of age<sup>51</sup> and smoking<sup>52</sup> have suggested that iron reduction (with ferritin and TSAT as endpoints) could be 386 387 of significant benefit for younger individuals and smokers. However, an overwhelming majority of the FeAST trial participants are males (~98%)<sup>23</sup>, therefore, sex-specific 388 389 differences could not be analyzed.

390

Taken together, our data suggest that iron redistribution to macrophages and reduced systemic iron availability may play a role in PAD. Some of the parameters analyzed are altered in a sex-specific manner implying that mechanisms of PAD development may differ between males and females. The strength of our study lies in the analyses of two independent cohorts, allowing for a generalization of the findings, an increased robustness

of the data, and a reduction of cohort-specific biases. In both cohorts, we observed a similar prevalence of PAD (~6%) associated with well-known risk factors (old age, diabetes, and hypertension). The examination of multiple iron biomarkers, including serum iron, ferritin, TSAT, and TIBC provides a comprehensive analysis of the relationship between iron and clinically apparent PAD. This is also the first study to evaluate the relationship between iron biomarkers and PAD in prediabetes and diabetes.

402

403 Limitations include the cross-sectional nature of the study which limits causal inferences and 404 precludes the assessment of temporal relationships. The HEIST-DiC cohort consisted of mainly European individuals with diabetes and prediabetes from a hospital-based study, 405 406 while NHANES is a survey cohort, representative of the US population, and therefore 407 contains a mix of ethnicities. Further, we were unable to control for all possible confounding 408 factors, such as genetic predisposition, lifestyle, medications, or other comorbidities. The 409 study described here also did not investigate potential mechanisms underlying the observed 410 associations.

411

#### 412 Conclusion

413 Overall, our findings suggest that "physiological" iron concentrations are safe for vascular 414 health. We also find evidence of an association between systemic iron biomarkers and PAD 415 specifically among females. Further studies are necessary to confirm whether the observed 416 associations are indeed causal and to explore the potential mechanisms underlying this 417 relationship. Understanding the role of iron in the development of PAD could lead to the 418 development of new preventive and therapeutic strategies for this condition. Our findings 419 need to be considered explorative to encourage the investigation of potential biological 420 pathways underlying the sex-specific differences in iron's influence on atherosclerosis.

421

#### 422 Ethics statement

423

The ethics committees of the University of Heidelberg approved this study (Decision No. 204/2004, 400/2010, and S-383/2016) according to the Declaration of Helsinki. All patients entered the study according to the guidelines of the local ethics committees following written informed consent to participate.

428

# 429 **Funding** 430

The HEIST-DiC study was funded by the Deutsche Forschungsgemeinschaft (SFB1118).
 MUM received funding from the DFG (SFB1118) and Translational Lung Research Center

433	Heidelberg (TLRC), German Center for Lung Research (DZL; Project No. FKZ
434	82DZL004A1).
435 436 437	Author contributions
438	Anand Ruban Agarvas: Conceptualization, Methodology, Software, Formal analysis,
439	Investigation, Data curation, Writing- Original draft, Visualization
440	Stefan Kopf: Investigation, Resources, Writing - Review & Editing
441	Paul Thalmann: Validation, Writing - Review & Editing
442	José Manuel Fernández-Real: Methodology, Writing - Review & Editing, Supervision
443	Peter Nawroth: Project administration, Funding acquisition, Supervision, Writing - Review &
444	Editing
445	Martina U. Muckenthaler: Conceptualization, Methodology, Supervision, Writing - Review &
446	Editing, Project administration, Funding acquisition
447 448	Conflict of interest
449	
450	None to declare
451 452	Data and Code Availability Statement
453	The data from this study can be explored here:
454	https://anandr.shinyapps.io/NHANES_HEISTDiC/. The HEIST-DiC dataset analyzed in the
455	current study is available from the corresponding authors on reasonable request. The
456	NHANES dataset is publicly available. Codes used for data analysis and visualization are
457	accessible here (https://github.com/griffindoc/pad)
450	
458 459 460	References
461	1. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease.
462	<i>Circ Res</i> . 2021;128(12):1818-1832. doi:10.1161/CIRCRESAHA.121.318535
463 464	2. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of

- 464 Sampson or, winams D, Mensan GA, Criqui MR. comparison of global estimates of
  465 prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review
  466 and analysis. *The Lancet*. 2013;382(9901):1329-1340. doi:10.1016/S0140-6736(13)61249-0
- Fowkes F, Murray G, Butcher I, Folsom A, Hirsch A, Couper D, DeBacker G, Kornitzer M,
   Newman A, Sutton-Tyrrell K, Cushman M, Lee A, Price J, D'Agostino R, Murabito J, Norman P,
   Masaki K, Bouter L, Heine R, Stehouwer C, McDermott M, Stoffers H, Knottnerus J, Ogren M,
   Hedblad B, Koenig W, Meisinger C, Cauley J, Franco O, Hunink M, Hofman A, Witteman J, Criqui
   M, Langer R, Hiatt W, Hamman R, Ankle Brachial Index Collaboration. Development and
   validation of an ankle brachial index risk model for the prediction of cardiovascular events. *Eur* J Prev Cardiolog. 2014;21(3):310-320. doi:10.1177/2047487313516564

- VA Million Veteran Program, Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee
   KM, Shao Q, Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, Wang
   L, Chen J, Saleheen D, Lee JS, Miller DR, Reaven P, Alba PR, Patterson OV, DuVall SL, Boden WE,
   Beckman JA, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, O'Donnell CJ,
   Kathiresan S, Tsao PS, Damrauer SM. Genome-wide association study of peripheral artery
   disease in the Million Veteran Program. *Nat Med*. 2019;25(8):1274-1279. doi:10.1038/s41591-
- 480 019-0492-5
- 481 5. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. *Cell*.
  482 2017;168(3):344-361. doi:10.1016/j.cell.2016.12.034
- 483 6. Sullivan JeromeL. IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK. *The Lancet*.
  484 1981;317(8233):1293-1294. doi:10.1016/S0140-6736(81)92463-6
- Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S,
   Seide SE, Sparla R, Hentze MW, Muckenthaler MU. Atherosclerosis is aggravated by iron
   overload and ameliorated by dietary and pharmacological iron restriction. *Eur Heart J*.
   Published online March 20, 2019. doi:10.1093/eurheartj/ehz112
- 489 8. Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John
  490 U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the
  491 study of health in Pomerania (SHIP). *Stroke*. 2004;35(2):453-457.
  492 doi:10.1161/01.STR.0000114875.31599.1C
- 493 9. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin Is Independently Associated
  494 With the Presence of Coronary Artery Calcium in 12 033 Men. *ATVB*. 2012;32(10):2525-2530.
  495 doi:10.1161/ATVBAHA.112.253088
- Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid
  atherosclerosis: prospective results from the Bruneck study. *Circulation*. 1997;96(10):33003307. doi:10.1161/01.cir.96.10.3300
- 499 11. Das De S, Krishna S, Jethwa A. Iron status and its association with coronary heart disease:
  500 systematic review and meta-analysis of prospective studies. *Atherosclerosis*. 2015;238(2):296501 303. doi:10.1016/j.atherosclerosis.2014.12.018
- 502 12. Guo S, Mao X, Li X, Ouyang H. Association between iron status and incident coronary artery
  503 disease: a population based-cohort study. *Sci Rep.* 2022;12(1):17490. doi:10.1038/s41598-022504 22275-0
- Klip IjT, Voors AA, Swinkels DW, Bakker SJL, Kootstra-Ros JE, Lam CS, Van Der Harst P, Van
   Veldhuisen DJ, Van Der Meer P. Serum ferritin and risk for new-onset heart failure and
   cardiovascular events in the community: Serum ferritin and risk for new-onset HF and CV
   events. Eur J Heart Fail. 2017;19(3):348-356. doi:10.1002/ejhf.622
- Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, INVENT
   Consortium, Tzoulaki I, Dehghan A. Effects of Genetically Determined Iron Status on Risk of
   Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization
   Study. J Am Heart Assoc. 2019;8(15):e012994. doi:10.1161/JAHA.119.012994
- 51315.Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of Blood Is Associated514with Reduced Risk of Myocardial Infarction: The Kuopio Ischaemic Heart Disease Risk Factor

- 515 Study. American Journal of Epidemiology. 1998;148(5):445-451.
- 516 doi:10.1093/oxfordjournals.aje.a009669
- Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body
  iron through blood donation on incident cardiac events. *Transfusion*. 2002;42(9):1135-1139.
  doi:10.1046/j.1537-2995.2002.00186.x
- Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association
  of a reduction in cardiovascular events with blood donation. *Heart*. 1997;78(2):188-193.
  doi:10.1136/hrt.78.2.188
- Peffer K, Den Heijer M, Holewijn S, De Graaf J, Swinkels DW, Verbeek ALM, Atsma F. The effect
   of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis:
   Subclinical Atherosclerosis in Blood Donors. *Transfusion*. 2013;53(7):1468-1474.
   doi:10.1111/j.1537-2995.2012.03916.x
- Riško P, Pláteník J, Buchal R, Potočková J, Kraml PJ. Long-term donors versus non-donor men:
   Iron metabolism and the atherosclerotic process. *Atherosclerosis*. 2018;272:14-20.
   doi:10.1016/j.atherosclerosis.2018.03.009
- Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron
  status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord*. 2009;9(1):34.
  doi:10.1186/1471-2261-9-34
- Ašćerić RR, Dimković NB, Trajković GŽ, Ristić BS, Janković AN, Durić PS, Ilijevski NS. Prevalence,
  clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a
  cross-sectional study. *BMC Nephrol*. 2019;20(1):281. doi:10.1186/s12882-019-1468-x
- Lien CT, Lin KC, Tsai YF, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with progression
  of peripheral arterial disease in hemodialysis patients. *Clin Exp Nephrol*. 2015;19(5):947-952.
  doi:10.1007/s10157-014-1074-y
- Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK,
  Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral
  Arterial Disease: A Randomized Controlled Trial. *JAMA*. 2007;297(6):603.
  doi:10.1001/jama.297.6.603
- Altamura S, Kopf S, Schmidt J, Müdder K, da Silva AR, Nawroth P, Muckenthaler MU.
  Uncoupled iron homeostasis in type 2 diabetes mellitus. *J Mol Med*. 2017;95(12):1387-1398.
  doi:10.1007/s00109-017-1596-3
- Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J,
   Cornberg M. EASL Clinical Practice Guidelines on haemochromatosis. *Journal of Hepatology*.
   2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033
- 26. Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, Zhu K, Zhang X, Liu Y, Lin X, Chen L, Shan Z, Liu L, Pan
  A, Liu G. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among
  Individuals With Type 2 Diabetes: Results From NHANES. *Diabetes Care*. 2022;45(6):1453-1461.
  doi:10.2337/dc21-2371
- 27. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U,
  Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley

- 555 M, Yeoman A. Guidelines on the management of abnormal liver blood tests. *Gut*. 2018;67(1):6-556 19. doi:10.1136/gutjnl-2017-314924
- 28. Ahlqvist E, Prasad RB, Groop L. Subtypes of Type 2 Diabetes Determined From Clinical
  Parameters. *Diabetes*. 2020;69(10):2086-2093. doi:10.2337/dbi20-0001
- 559 Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De 29. 560 Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther 561 J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, ESC Scientific 562 Document Group, Widimsky P, Kolh P, Agewall S, Bueno H, Coca A, De Borst GJ, Delgado V, Dick 563 F, Erol C, Ferrini M, Kakkos S, Katus HA, Knuuti J, Lindholt J, Mattle H, Pieniazek P, Piepoli MF, 564 Scheinert D, Sievert H, Simpson I, Sulzenko J, Tamargo J, Tokgozoglu L, Torbicki A, Tsakountakis 565 N, Tuñón J, De Ceniga MV, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, 566 Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, lung B, Juni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli 567 568 MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Zelveian PH, 569 Haumer M, Isachkin D, De Backer T, Dilic M, Petrov I, Kirhmajer MV, Karetova D, Prescott E, 570 Soliman H, Paapstel A, Makinen K, Tosev S, Messas E, Pagava Z, Müller OJ, Naka KK, Járai Z, et 571 al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in 572 collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 573 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095
- 30. R Core Team. R: A Language and Environment for Statistical Computing. Published online 2022.
   https://www.R-project.org/
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative.
  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
  statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457.
  doi:10.1016/S0140-6736(07)61602-X
- Allaire J. quarto: R Interface to "Quarto" Markdown Publishing System\_. R package version 1.2.
   Published online 2022. https://CRAN.R-project.org/package=quarto
- S82 33. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, Borges
  S83 B. Shiny: Web Application Framework for R\_. R package version 1.7.4.1. Published online 2023.
  S84 https://CRAN.R-project.org/package=shiny
- 34. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum Ferritin and C282Y
  Mutation of the Hemochromatosis Gene as Predictors of Asymptomatic Carotid
  Atherosclerosis in a Community Population. *Stroke*. 2000;31(12):3015-3020.
  doi:10.1161/01.STR.31.12.3015
- Shou J, Zhao R, Wang D, Gao Q, Zhao D, Ouyang B, Hao L, Peng X. Sex-Specific Association
  Between Iron Status and the Predicted 10-Year Risk for Atherosclerotic Cardiovascular Disease
  in Hypertensive Patients. *Biol Trace Elem Res.* 2022;200(11):4594-4607. doi:10.1007/s12011021-03060-y
- 593 36. Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific
  594 mortality by moderately and markedly increased ferritin concentrations: general population
  595 study and metaanalysis. *Clin Chem.* 2014;60(11):1419-1428.
  596 dei:10.1272 (simplem: 2014.220012)
- 596 doi:10.1373/clinchem.2014.229013

59737.Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P. The598association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The599English longitudinal study of ageing. PLoS One. 2017;12(6):e0178994.

- 600 doi:10.1371/journal.pone.0178994
- Amar Z, Talpur AS, Zafar S, Memon A, Nazary K, Esmati S, Hashim S, Maqsood H, Hafizyar F,
  Kumar B. Comparison of Iron Profile in Patients With and Without Coronary Heart Disease. *Cureus*. Published online June 12, 2021. doi:10.7759/cureus.15613
- Vega De Céniga M, Bravo E, Izagirre M, Casco C, Estallo L, Esteban M, Barba A. Anaemia, Iron
  and Vitamin Deficits in Patients with Peripheral Arterial Disease. *European Journal of Vascular and Endovascular Surgery*. 2011;41(6):828-830. doi:10.1016/j.ejvs.2011.01.017
- 40. Otaki Y, Watanabe T, Takahashi H, Sugai T, Yokoyama M, Tamura H, Kato S, Nishiyama S,
  Arimoto T, Shishido T, Watanabe M. Impact of Iron Deficiency on Peripheral Artery Disease
  After Endovascular Therapy. *Circ Rep.* 2019;1(4):187-195. doi:10.1253/circrep.CR-18-0029
- 61041.Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart611disease. N Engl J Med. 1994;330(16):1119-1124. doi:10.1056/NEJM199404213301604
- Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I. Which is the best way for estimating
  transferrin saturation? *Renal Failure*. 2010;32(8):1022-1023.
  doi:10.3109/0886022X.2010.502609
- 43. Vinchi F, Sparla R, Passos ST, Sharma R, Vance SZ, Zreid HS, Juaidi H, Manwani D, Yazdanbakhsh
  K, Nandi V, Silva AMN, Agarvas AR, Fibach E, Belcher JD, Vercellotti GM, Ghoti H, Muckenthaler
  MU. Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in
  transfusion-dependent patients with haemolytic anaemias. *Br J Haematol*. 2021;193(3):637658. doi:10.1111/bjh.17361
- Friedrich N, Milman N, Völzke H, Linneberg A, Jørgensen T. Is serum ferritin within the
  reference range a risk predictor of cardiovascular disease? A population-based, long-term
  study comprising 2874 subjects. *Br J Nutr*. 2009;102(4):594-600.
  doi:10.1017/S000711450922085X
- 624 45. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin
  625 saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic
  626 Followup Study. National Health and Nutrition Examination Survey. *Am J Epidemiol.*627 1996;144(1):59-68. doi:10.1093/oxfordjournals.aje.a008855
- 46. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR.
  Cytokine signatures in atherosclerotic claudicants. *Journal of Surgical Research*.
  2003;111(2):215-221. doi:10.1016/S0022-4804(03)00075-1
- 47. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative
  mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101(7):24612463. doi:10.1182/blood-2002-10-3235
- 634 48. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU. A
  635 novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. *Blood*.
  636 2015;125(14):2265-2275. doi:10.1182/blood-2014-08-595256

- 49. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases:
  from mechanisms to treatment options in anemia of inflammation. *Blood*. 2022;140(19):20112023. doi:10.1182/blood.2021013472
- 50. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D liang, Crooks DR, Sougrat R,
  Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is
  derived primarily from macrophages through a nonclassical secretory pathway. *Blood*.
  2010;116(9):1574-1584. doi:10.1182/blood-2009-11-253815
- 51. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on
  clinical outcomes in peripheral arterial disease. *American Heart Journal*. 2011;162(5):949957.e1. doi:10.1016/j.ahj.2011.08.013
- 52. DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and
  clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and nonsmokers. *Vascular*. 2013;21(4):233-241. doi:10.1177/1708538113478776

651

## 652 Legends

## 653 **Table 1. Demographics of HEIST-DiC participants**

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein,
HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular
Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6,
hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR:
Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

663

## 664 Table 2. Demographics of NHANES 1999-2004 participants

The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)- survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test and significant P-values are boldfaced.

671 BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, 672 HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated 673 Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity,

AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4: Fibrosis-4 index

- 675
- 676

## 677 Figure 1. Odds Ratio plot of iron parameters with PAD: HEIST-DiC participants

The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval) derived from the logistic regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

684

## 685 Figure 2. The coefficient plot of iron parameters with ICAM-1: HEIST-DiC participants

The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived
from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.
Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes
and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High
sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

691

Figure 3. The coefficient plot of iron parameters with VCAM-1: HEIST-DiC participants
 The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived

from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

698

## Figure 4. The Odds Ratio plot of iron parameters with PAD: NHANES 1900-2004 participants

The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval) derived from the logistic regression analysis (sex-stratified) of each of the iron parameters with PAD.

Model 1: represents the univariate analysis. Model 2: adjusted for age, ethnicity, BMI and smoking. Model 3: adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and

hypertension, FIB4 score, Urine Albumin-Creatinine Ratio, and C-reactive protein. Model 4:
 adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and hypertension, FIB4
 score, Urine Albumin-Creatinine Ratio, C-reactive protein, LDL, antihyperlipidemic and
 antiplatelet medications, and HOMA2-IR.

711 Supplementary files

## 713 Supplementary Table 1. Model 4 Regression Summary NHANES 1999-2004.

The table shows the regression results of the multivariate Model 4 analysis of iron biomarkers with PAD. The Odds ratio, 95% confidence interval, and p-value are shown in the table. The significant associations are highlighted in bold.

717 718

710

712

## 719 Supplementary Table 2. Data fields and variables from NHANES 1999-2004.

The table shows the variables and the corresponding codes used for accessing data from the NHANES. The hyperlinks to the procedure manuals and datafiles are also provided in the table.

723

## 724 Supplementary Figure 1. The Odds Ratio plot of iron parameters with PAD: Sensitivity

725 analysis of NHANES 1900-2004 participants

		Male	s (N=192)			Femal	es (N=165)		
Variable	Ν	No PAD N = 175	PAD N = 17	P-value	Ν	No PAD N = 159	$\begin{array}{c} PAD \\ N = 6^1 \end{array}$	P-value	
Age	192	60 (11)	70 (8)	<0.001	165	59 (11)	68 (7)	0.025	
BMI	192	29.8 (5.1)	30.8 (6.0)	0.6	165	29.6 (6.3)	34.6 (5.1)	0.036	
Hypertension	192			0.09 <sup>F</sup>				0.028 <sup>F</sup>	
No	70	67 (38%)	3 (18%)		82	82 (52%)	0 (0%)		
Yes	122	108 (62%)	14 (82%)		165	77 (48%)	6 (100%)		
Diabetes	192			0.067 <sup>F</sup>	165			0.3 <sup>F</sup>	
No diabetes	37	37 (21%)	0 (0%)		67	66 (42%)	1 (17%)		
Prediabetes	19	17 (9.7%)	2 (12%)		18	18 (11%)	0 (0%)		
Diabetes	136	121 (69%)	15 (88%)		80	75 (47%)	5 (83%)		
Dietary management (=Yes)	192	19 (11%)	3 (18%)	0.4 <sup>F</sup>	165	9 (5.7%)	1 (17%)	0.3 <sup>F</sup>	
Oral antidiabetic medications (=Yes)	192	60 (34%)	7 (41%)	0.6 <sup>F</sup>	165	41 (26%)	2 (33%)	0.7 <sup>F</sup>	
Statins (=Yes)	192	57 (33%)	6 (35%)	0.8 <sup>F</sup>	165	27 (17%)	2 (33%)	0.3 <sup>F</sup>	
Fasting blood glucose (mg/dL)	192	135 (47)	175 (59)	0.002	165	121 (40)	157 (50)	0.067	
HbA1c (g/dL)	192	6.78 (3.10)	7.40 (1.43)	0.014	165	6.25 (1.19)	7.13 (1.13)	0.056	

## Table 1. Baseline characteristics of HEIST-DiC participants

Insulin	192	30 (17%)	5 (29%)	0.2	165	22 (14%)	2 (33%)	0.2
Parameters of vascul	ar functi	ion						
Ankle-brachial index (Right)	191	1.11 (0.08)	0.84 (0.11)	<0.001	164	1.09 (0.08)	0.81 (0.06)	<0.001
Ankle-brachial index (Left)	191	1.12 (0.08)	0.90 (0.09)	<0.001	161	1.09 (0.08)	0.93 (0.08)	<0.001
Carotid intima- media thickness (mm)	176	0.63 (0.16)	0.71 (0.13)	0.025	161	0.59 (0.13)	0.83 (0.17)	0.002
Carotid-femoral Pulse Wave Velocity	185	8.79 (1.79)	10.43 (1.94)	0.004	163	8.43 (1.86)	11.80 (1.24)	0.002
ICAM1	162	287 (104)	363 (93)	0.008	134	308 (111)	269 (82)	0.6
VCAM1	162	869 (247)	1,035 (282)	0.017	134	828 (211)	743 (240)	0.8
Other laboratory para	meters							
Triglycerides (mg/dL)	192	171 (166)	204 (100)	0.011	165	140 (93)	384 (567)	0.092
Cholesterol (mg/dL)	192	190 (47)	197 (59)	0.8	165	206 (42)	194 (41)	0.5
HDL (mg/dL)	192	49 (13)	43 (8)	0.067	165	61 (18)	55 (29)	0.3
LDL (mg/dL)	179	111 (42)	108 (37)	0.9	158	118 (35)	93 (23)	0.088
Hemoglobin (g/dL)	192	14.85 (1.06)	14.41 (1.26)	0.14	165	13.59 (0.93)	13.23 (1.30)	0.5
Mean Corpuscular	192	88.8 (4.6)	91.2 (5.7)	0.2	165	88.3 (4.2)	87.7 (5.0)	0.7

Volume (fL)								
hsCRP	184	2.11 (3.10)	3.68 (5.82)	0.3	159	3.5 (4.2)	7.9 (7.4)	0.083
IL6	150	3.16 (1.85)	4.44 (2.98)	0.010	128	3.42 (2.02)	4.50 (2.47)	0.3
hsTNT	174	10.8 (9.3)	13.7 (6.8)	0.033	147	7.1 (5.2)	11.6 (10.1)	0.2
proBNP	174	136 (365)	155 (149)	0.052	147	113 (197)	229 (149)	0.008
eGFR (ml/min/1.73m²)	192	91 (17)	76 (17)	0.002	165	91 (16)	67 (25)	0.016
Urinary Albumin Creatinine Ratio (mg/g)	188	81 (454)	130 (229)	0.001	164	29 (104)	72 (94)	0.012
Iron-related parameter	ers							
Iron	192	17.8 (5.9)	18.1 (7.5)	0.7	165	16.9 (5.8)	18.0 (5.9)	0.6
Ferritin	192	189 (157)	232 (134)	0.10	165	99 (81)	198 (146)	0.031
Transferrin	189	2.41 (0.31)	2.41 (0.37)	0.6	161	2.47 (0.38)	2.57 (0.38)	0.6
TSAT (%)	189	27 (9)	23 (6)	0.2	159	25 (9)	22 (10)	0.5

### Table 1. Demographics of HEIST-DiC participants

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test<sup>F</sup> and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6, hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

		Males	6			Female	es	
Characteristic	Overall (N =5454)	No PAD (N =5067)	PAD (N =387)	P- value	Overall (N =3882)	No PAD (N =3519)	No PAD (N =363)	P- value
Ethnicity								
Non-Hispanic White	2,323 (79)	2,114 (79)	209 (84)	<b>0.003</b> <sup>F</sup>	1,600 (75)	1,418 (74)	182 (78)	0.005 <sup>F</sup>
Non-Hispanic Black	742 (8.6)	677 (8.5)	65 (10)		647 (11)	573 (11)	74 (14)	
Mexican-American	871 (4.7)	812 (4.8)	59 (4.2)		676 (4.4)	621 (4.4)	55 (3.9)	
Others	252 (7.3)	244 (7.6)	8 (1.2)		261 (10)	245 (11)	16 (4.4)	
Age (years)	52 (45, 61)	51 (45, 60)	69 (61, 75)	<0.001	52 (46, 67)	52 (45, 65)	71 (58, 79)	<0.001
BMI (kg/m²)	27.9 (25.2, 30.8)	27.9 (25.2, 30.8)	28.0 (25.1, 32.0)	0.8	27 (24, 32)	27 (24, 32)	29 (25, 34)	0.014
Diabetes (coded)								
No diabetes	2,664 (74)	2,525 (62.6)	139 (3.4)	<0.001 <sup>F</sup>	1,968 (72)	1,829 (59.4)	139 (4.5)	<0.001 <sup>F</sup>
Prediabetes	643 (12)	548 (13.6)	95 (2.4)		568 (15)	484 (14.7)	84 (2.7)	
Diabetes	730 (14)	637 (15.8)	93 (2.3)		545 (13)	454 (15.7)	91 (3.0)	
Hypertension (coded)								
No	355 (22)	331 (19.9)	24 (1.5)	<b>0.026</b> <sup>F</sup>	273 (21)	246 (17)	27 (1.9)	0.6 <sup>F</sup>
Yes	1,302 (78)	1,137 (68.6)	165 (9.9)		1,173 (79)	1,003 (69.4)	170 (11.8)	
Smoking (coded)								

## Table 2. Demographics of NHANES 1999-2004 participants

		i						
Nonsmoker	1,488 (37)	1,419 (33.9)	69 (1.7)	<b>&lt;0.001</b> <sup>F</sup>	1,899 (57)	1,729 (54.4)	170 (5.4)	0.2 <sup>F</sup>
Former smoker	1,776 (41)	1,602 (38.3)	174 (4.2)		792 (26)	692 (21.8)	100 (3.1)	
Current smoker	919 (22)	821 (19.6)	98 (2.3)		487 (17)	431 (13.6)	56 (1.8)	
Alcohol drinker (code	d)							
No	282 (34)	263 (33.2)	19 (2.4)	0.6 <sup>F</sup>	723 (43)	632 (41.8)	91 (6.01)	>0.9 <sup>F</sup>
Yes	511 (66)	470 (59.3)	41 (5.2)		790 (57)	690 (45.6)	100 (6.6)	
Physical activity (code	ed)							
Sedentary	1,922 (42)	1,758 (42.9)	164 (4)	0.8 <sup>F</sup>	1,550 (43)	1,379 (45.2)	171 (5.6)	0.087 <sup>F</sup>
Low to Moderate	1,313 (38)	1,220 (29.8)	93 (2.3)		938 (37)	851 (27.9)	87 (2.9)	
Vigorous	863 (20)	793 (19.4)	70 (1.71)		564 (20)	524 (17.2)	40 (1.3)	
Antihyperlipidemic m	edications (code	ed)						
No	3,118 (82)	2,866 (76.4)	252 (6.7)	<0.001 <sup>F</sup>	2,519 (87)	2,277 (77.9)	242 (8.3)	<0.001 <sup>F</sup>
Yes	634 (18)	560 (14.9)	74 (1.97)		405 (13)	337 (11.5)	68 (2.3)	
Antiplatelet medicatio	ns (coded)							
No	3,665 (98)	3,359 (89.5)	306 (8.2)	<0.001 <sup>F</sup>	2,861 (98)	2,563 (68.3)	298 (7.9)	<b>0.006</b> <sup>F</sup>
Yes	87 (1.6)	67 (1.8)	20 (0.5)		63 (1.7)	51 (1.4)	12 (0.3)	
Ankle-brachial Index (Left)	1.16 (1.10, 1.22)	1.17 (1.11, 1.22)	0.87 (0.79, 0.98)	<0.001	1.11 (1.04, 1.19)	1.12 (1.06, 1.19)	0.88 (0.78, 0.96)	<0.001
Ankle-brachial Index (Right)	1.16 (1.10, 1.22)	1.16 (1.11, 1.22)	0.87 (0.75, 0.96)	<0.001	1.10 (1.03, 1.18)	1.11 (1.05, 1.19)	0.86 (0.77, 0.90)	<0.001

Albumin (g/L)	44.0 (42.0, 46.0)	44.0 (42.0, 46.0)	43.0 (41.0, 45.0)	<0.001	43.0 (41.0, 44.4)	43.0 (41.0, 45.0)	42.0 (39.0, 44.0)	0.003
AST (U/L)	26 (21, 33)	26 (21, 34)	22 (18, 27)	<0.001	19 (16, 25)	19 (16, 25)	20 (16, 25)	0.9
ALT (U/L)	24 (21, 29)	24 (21, 29)	23 (20, 29)	0.2	21 (18, 25)	21 (18, 25)	22 (19, 26)	0.087
Blood urea nitrogen (mmol/L)	5.36 (4.28, 6.10)	5.00 (4.28, 6.10)	6.07 (4.64, 7.14)	<0.001	4.60 (3.57, 5.71)	4.60 (3.57, 5.71)	5.00 (3.90, 7.14)	0.010
Creatinine (µmol/L)	88 (71, 97)	88 (71, 97)	88 (80, 115)	0.002	62 (62, 80)	62 (53, 71)	80 (62, 88)	<0.001
Total Cholesterol (mmol/L)	5.22 (4.55, 5.89)	5.22 (4.55, 5.90)	4.86 (4.04, 5.58)	0.003	5.33 (4.71, 6.03)	5.33 (4.71, 6.03)	5.38 (4.81, 5.95)	0.7
Triacylglycerols (mmol/L)	1.49 (1.01, 2.24)	1.49 (1.01, 2.24)	1.47 (0.97, 2.37)	0.8	1.22 (0.81, 1.82)	1.20 (0.80, 1.78)	1.59 (1.09, 2.45)	<0.001
LDL (mmol/L)	3.16 (2.61, 3.75)	3.18 (2.61, 3.78)	2.85 (2.17, 3.41)	0.025	3.13 (2.59, 3.72)	3.13 (2.59, 3.72)	3.05 (2.50, 3.62)	0.8
HDL (mmol/L)	1.14 (0.98, 1.39)	1.14 (0.98, 1.40)	1.16 (0.96, 1.34)	0.6	1.45 (1.19, 1.73)	1.45 (1.22, 1.73)	1.32 (1.11, 1.55)	0.001
Fasting plasma glucose (mmol/L)	5.62 (5.24, 6.21)	5.61 (5.25, 6.16)	5.89 (5.18, 6.73)	0.5	5.29 (4.97, 5.79)	5.28 (4.95, 5.74)	5.81 (5.36, 6.93)	<0.001
Insulin (pmol/L)	57 (38, 91)	57 (38, 90)	70 (41, 108)	0.14	46 (32, 79)	46 (31, 74)	106 (47, 190)	<0.001
CRP (mg/dL)	0.17 (0.08, 0.35)	0.17 (0.08, 0.35)	0.26 (0.17, 0.43)	<0.001	0.25 (0.10, 0.58)	0.25 (0.10, 0.57)	0.33 (0.15, 0.90)	0.009
Hemoglobin (g/dL)	15.20 (14.60, 16.00)	15.20 (14.70, 16.00)	14.90 (14.10, 15.60)	<0.001	13.80 (13.10, 14.50)	13.90 (13.10, 14.50)	13.80 (12.90, 14.80)	>0.9


FIB4 Score	1.15 (0.91, 1.51)	1.14 (0.90, 1.50)	1.35 (1.10, 1.67)	<0.001	0.87 (0.64, 1.17)	0.84 (0.63, 1.15)	1.11 (0.83, 1.44)	<0.001
Albumin-creatinine ratio (μg/mg)	0.60 (0.41, 1.06)	0.58 (0.40, 1.00)	1.13 (0.65, 2.78)	<0.001	0.80 (0.54, 1.51)	0.77 (0.53, 1.40)	1.30 (0.70, 2.59)	<0.001
lron (μg/dL)	91 (72, 115)	92 (73, 115)	80 (64, 108)	<0.001	78 (60, 99)	79 (60, 99)	75 (57, 96)	0.2
Ferritin (μg/dL)	146 (96, 259)	146 (97, 258)	127 (81, 262)	0.5	64 (32, 109)	62 (31, 106)	87 (56, 252)	<0.001
TSAT (%)	26 (21, 33)	26 (21, 33)	24 (17, 30)	0.021	22 (16, 29)	22 (16, 29)	20 (16, 30)	0.5
TIBC (μmol/L)	63 (57, 70)	63 (57, 70)	65 (58, 72)	0.5	63 (58, 71)	64 (58, 71)	60 (54, 68)	0.001

## Table 2. Demographics of NHANES 1999-2004 participants


The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)-survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test<sup>F</sup> and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4 Score: Fibrosis-4 index Score


## Serum iron indices vs PAD: HEIST–DiC



## Serum iron indices vs ICAM1: HEIST–DiC



## Serum iron indices vs VCAM1: HEIST–DiC



## Iron parameters vs PAD: NHANES

